Novartis Ag (NVSEF) EBT Margin (2016 - 2025)
Historic EBT Margin for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to 388.65%.
- Novartis Ag's EBT Margin rose 3636700.0% to 388.65% in Q4 2025 from the same period last year, while for Dec 2025 it was 497.63%, marking a year-over-year increase of 4705200.0%. This contributed to the annual value of 29.99% for FY2025, which is 28800.0% up from last year.
- According to the latest figures from Q4 2025, Novartis Ag's EBT Margin is 388.65%, which was up 3636700.0% from 574.79% recorded in Q3 2025.
- Novartis Ag's EBT Margin's 5-year high stood at 670.78% during Q1 2025, with a 5-year trough of 13.17% in Q3 2023.
- Moreover, its 5-year median value for EBT Margin was 24.88% (2021), whereas its average is 125.67%.
- In the last 5 years, Novartis Ag's EBT Margin plummeted by -1133000bps in 2022 and then surged by 6443200bps in 2025.
- Novartis Ag's EBT Margin (Quarter) stood at 128.14% in 2021, then crashed by -88bps to 14.84% in 2022, then skyrocketed by 40bps to 20.81% in 2023, then rose by 20bps to 24.98% in 2024, then surged by 1456bps to 388.65% in 2025.
- Its EBT Margin was 388.65% in Q4 2025, compared to 574.79% in Q3 2025 and 423.06% in Q2 2025.